Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 2222 entries
Sorted by: Best Match Show Resources per page
Dietary glucose regulates yeast consumption in adult Drosophila males.

Frontiers in physiology

Lebreton S, Witzgall P, Olsson M, Becher PG.
PMID: 25566097
Front Physiol. 2014 Dec 22;5:504. doi: 10.3389/fphys.2014.00504. eCollection 2014.

The adjustment of feeding behavior in response to hunger and satiety contributes to homeostatic regulation in animals. The fruit fly Drosophila melanogaster feeds on yeasts growing on overripe fruit, providing nutrients required for adult survival, reproduction and larval growth....

Cite
Lebreton S, Witzgall P, Olsson M, et al. Dietary glucose regulates yeast consumption in adult Drosophila males. Front Physiol. 2014;5:504doi: 10.3389/fphys.2014.00504.
Lebreton, S., Witzgall, P., Olsson, M., & Becher, P. G. (2014). Dietary glucose regulates yeast consumption in adult Drosophila males. Frontiers in physiology, 5504. https://doi.org/10.3389/fphys.2014.00504
Lebreton, Sébastien, et al. "Dietary glucose regulates yeast consumption in adult Drosophila males." Frontiers in physiology vol. 5 (2014): 504. doi: https://doi.org/10.3389/fphys.2014.00504
Lebreton S, Witzgall P, Olsson M, Becher PG. Dietary glucose regulates yeast consumption in adult Drosophila males. Front Physiol. 2014 Dec 22;5:504. doi: 10.3389/fphys.2014.00504. eCollection 2014. PMID: 25566097; PMCID: PMC4273620.
Copy Download .nbib Format: NLM
The γ-secretase inhibitors enhance the anti-leukemic activity of ibrutinib in B-CLL cells.

Oncotarget

Secchiero P, Voltan R, Rimondi E, Melloni E, Athanasakis E, Tisato V, Gallo S, Rigolin GM, Zauli G.
PMID: 28938632
Oncotarget. 2017 Jul 22;8(35):59235-59245. doi: 10.18632/oncotarget.19494. eCollection 2017 Aug 29.

Ibrutinib blocks B-cell receptor signaling and interferes with leukemic cell-to-microenvironment interactions. Ibrutinib plays a key role in the management of B-CLL and is recommended for first line treatment of high-risk CLL patients with 17p deletion. Therefore, elucidating the factors...

Cite
Secchiero P, Voltan R, Rimondi E, et al. The γ-secretase inhibitors enhance the anti-leukemic activity of ibrutinib in B-CLL cells. Oncotarget. 2017;8(35):59235-59245doi: 10.18632/oncotarget.19494.
Secchiero, P., Voltan, R., Rimondi, E., Melloni, E., Athanasakis, E., Tisato, V., Gallo, S., Rigolin, G. M., & Zauli, G. (2017). The γ-secretase inhibitors enhance the anti-leukemic activity of ibrutinib in B-CLL cells. Oncotarget, 8(35), 59235-59245. https://doi.org/10.18632/oncotarget.19494
Secchiero, Paola, et al. "The γ-secretase inhibitors enhance the anti-leukemic activity of ibrutinib in B-CLL cells." Oncotarget vol. 8,35 (2017): 59235-59245. doi: https://doi.org/10.18632/oncotarget.19494
Secchiero P, Voltan R, Rimondi E, Melloni E, Athanasakis E, Tisato V, Gallo S, Rigolin GM, Zauli G. The γ-secretase inhibitors enhance the anti-leukemic activity of ibrutinib in B-CLL cells. Oncotarget. 2017 Jul 22;8(35):59235-59245. doi: 10.18632/oncotarget.19494. eCollection 2017 Aug 29. PMID: 28938632; PMCID: PMC5601728.
Copy Download .nbib Format: NLM
RRx-001-Induced Tumor Necrosis and Immune Cell Infiltration in an EGFR Mutation-Positive NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors: A Case Report.

Case reports in oncology

Brzezniak C, Schmitz BA, Peterson PG, Degesys A, Oronsky BT, Scicinski JJ, Caroen SZ, Carter CA.
PMID: 26933418
Case Rep Oncol. 2016 Jan 15;9(1):45-50. doi: 10.1159/000443605. eCollection 2016.

We present the case of a 49-year-old male with metastatic epidermal growth factor receptor (EGFR) mutation-positive adenocarcinoma of the lung that continues to outlive stage IV diagnosis of non-small cell lung cancer after treatment with RRx-001, an experimental anticancer...

Cite
Brzezniak C, Schmitz BA, Peterson PG, et al. RRx-001-Induced Tumor Necrosis and Immune Cell Infiltration in an EGFR Mutation-Positive NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors: A Case Report. Case Rep Oncol. 2016;9(1):45-50doi: 10.1159/000443605.
Brzezniak, C., Schmitz, B. A., Peterson, P. G., Degesys, A., Oronsky, B. T., Scicinski, J. J., Caroen, S. Z., & Carter, C. A. (2016). RRx-001-Induced Tumor Necrosis and Immune Cell Infiltration in an EGFR Mutation-Positive NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors: A Case Report. Case reports in oncology, 9(1), 45-50. https://doi.org/10.1159/000443605
Brzezniak, Christina, et al. "RRx-001-Induced Tumor Necrosis and Immune Cell Infiltration in an EGFR Mutation-Positive NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors: A Case Report." Case reports in oncology vol. 9,1 (2016): 45-50. doi: https://doi.org/10.1159/000443605
Brzezniak C, Schmitz BA, Peterson PG, Degesys A, Oronsky BT, Scicinski JJ, Caroen SZ, Carter CA. RRx-001-Induced Tumor Necrosis and Immune Cell Infiltration in an EGFR Mutation-Positive NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors: A Case Report. Case Rep Oncol. 2016 Jan 15;9(1):45-50. doi: 10.1159/000443605. eCollection 2016. PMID: 26933418; PMCID: PMC4748757.
Copy Download .nbib Format: NLM
Sports and childhood brain tumors: Can I play?.

Neuro-oncology practice

Perreault S, Lober RM, Davis C, Stave C, Partap S, Fisher PG.
PMID: 26034627
Neurooncol Pract. 2014 Dec;1(4):158-165. doi: 10.1093/nop/npu020. Epub 2014 Sep 01.

BACKGROUND: It is unknown whether children with brain tumors have a higher risk of complications while participating in sports. We sought to estimate the prevalence of such events by conducting a systematic review of the literature, and we surveyed...

Cite
Perreault S, Lober RM, Davis C, et al. Sports and childhood brain tumors: Can I play?. Neurooncol Pract. 2014;1(4):158-165doi: 10.1093/nop/npu020.
Perreault, S., Lober, R. M., Davis, C., Stave, C., Partap, S., & Fisher, P. G. (2014). Sports and childhood brain tumors: Can I play?. Neuro-oncology practice, 1(4), 158-165. https://doi.org/10.1093/nop/npu020
Perreault, Sébastien, et al. "Sports and childhood brain tumors: Can I play?." Neuro-oncology practice vol. 1,4 (2014): 158-165. doi: https://doi.org/10.1093/nop/npu020
Perreault S, Lober RM, Davis C, Stave C, Partap S, Fisher PG. Sports and childhood brain tumors: Can I play?. Neurooncol Pract. 2014 Dec;1(4):158-165. doi: 10.1093/nop/npu020. Epub 2014 Sep 01. PMID: 26034627; PMCID: PMC4369718.
Copy Download .nbib Format: NLM
A Drug Combination Screen Identifies Drugs Active against Amoxicillin-Induced Round Bodies of In Vitro Borrelia burgdorferi Persisters from an FDA Drug Library.

Frontiers in microbiology

Feng J, Shi W, Zhang S, Sullivan D, Auwaerter PG, Zhang Y.
PMID: 27242757
Front Microbiol. 2016 May 23;7:743. doi: 10.3389/fmicb.2016.00743. eCollection 2016.

Although currently recommended antibiotics for Lyme disease such as doxycycline or amoxicillin cure the majority of the patients, about 10-20% of patients treated for Lyme disease may experience lingering symptoms including fatigue, pain, or joint and muscle aches. Under...

Cite
Feng J, Shi W, Zhang S, et al. A Drug Combination Screen Identifies Drugs Active against Amoxicillin-Induced Round Bodies of In Vitro Borrelia burgdorferi Persisters from an FDA Drug Library. Front Microbiol. 2016;7:743doi: 10.3389/fmicb.2016.00743.
Feng, J., Shi, W., Zhang, S., Sullivan, D., Auwaerter, P. G., & Zhang, Y. (2016). A Drug Combination Screen Identifies Drugs Active against Amoxicillin-Induced Round Bodies of In Vitro Borrelia burgdorferi Persisters from an FDA Drug Library. Frontiers in microbiology, 7743. https://doi.org/10.3389/fmicb.2016.00743
Feng, Jie, et al. "A Drug Combination Screen Identifies Drugs Active against Amoxicillin-Induced Round Bodies of In Vitro Borrelia burgdorferi Persisters from an FDA Drug Library." Frontiers in microbiology vol. 7 (2016): 743. doi: https://doi.org/10.3389/fmicb.2016.00743
Feng J, Shi W, Zhang S, Sullivan D, Auwaerter PG, Zhang Y. A Drug Combination Screen Identifies Drugs Active against Amoxicillin-Induced Round Bodies of In Vitro Borrelia burgdorferi Persisters from an FDA Drug Library. Front Microbiol. 2016 May 23;7:743. doi: 10.3389/fmicb.2016.00743. eCollection 2016. PMID: 27242757; PMCID: PMC4876775.
Copy Download .nbib Format: NLM
Death after Sexual Intercourse.

Case reports in emergency medicine

Braun CT, Ricklin ME, Pauli A, Ott D, Exadaktylos AK, Pfortmueller CA.
PMID: 26697238
Case Rep Emerg Med. 2015;2015:646438. doi: 10.1155/2015/646438. Epub 2015 Dec 01.

Sexuality is an essential aspect of quality of life. Nevertheless, sexual intercourse is physically challenging and leads to distinct changes in blood pressure, heart, and respiratory rate that may lead to vital complications. We present a case report of...

Cite
Braun CT, Ricklin ME, Pauli A, et al. Death after Sexual Intercourse. Case Rep Emerg Med. 2015;2015:646438doi: 10.1155/2015/646438.
Braun, C. T., Ricklin, M. E., Pauli, A., Ott, D., Exadaktylos, A. K., & Pfortmueller, C. A. (2015). Death after Sexual Intercourse. Case reports in emergency medicine, 2015646438. https://doi.org/10.1155/2015/646438
Braun, Christian T, et al. "Death after Sexual Intercourse." Case reports in emergency medicine vol. 2015 (2015): 646438. doi: https://doi.org/10.1155/2015/646438
Braun CT, Ricklin ME, Pauli A, Ott D, Exadaktylos AK, Pfortmueller CA. Death after Sexual Intercourse. Case Rep Emerg Med. 2015;2015:646438. doi: 10.1155/2015/646438. Epub 2015 Dec 01. PMID: 26697238; PMCID: PMC4678062.
Copy Download .nbib Format: NLM
Efficacy and safety evaluation of pentoxifylline associated with other antioxidants in medical treatment of Peyronie's disease: a case-control study.

Research and reports in urology

Paulis G, Barletta D, Turchi P, Vitarelli A, Dachille G, Fabiani A, Gennaro R.
PMID: 26770906
Res Rep Urol. 2015 Dec 31;8:1-10. doi: 10.2147/RRU.S97194. eCollection 2016.

Peyronie's disease (PD) is a chronic disorder involving the tunica albuginea surrounding the corpora cavernosa of the penis. A conservative treatment is indicated in the first stage of disease. The aim of this study was to assess the therapeutic...

Cite
Paulis G, Barletta D, Turchi P, et al. Efficacy and safety evaluation of pentoxifylline associated with other antioxidants in medical treatment of Peyronie's disease: a case-control study. Res Rep Urol. 2015;8:1-10doi: 10.2147/RRU.S97194.
Paulis, G., Barletta, D., Turchi, P., Vitarelli, A., Dachille, G., Fabiani, A., & Gennaro, R. (2016). Efficacy and safety evaluation of pentoxifylline associated with other antioxidants in medical treatment of Peyronie's disease: a case-control study. Research and reports in urology, 81-10. https://doi.org/10.2147/RRU.S97194
Paulis, Gianni, et al. "Efficacy and safety evaluation of pentoxifylline associated with other antioxidants in medical treatment of Peyronie's disease: a case-control study." Research and reports in urology vol. 8 (2016): 1-10. doi: https://doi.org/10.2147/RRU.S97194
Paulis G, Barletta D, Turchi P, Vitarelli A, Dachille G, Fabiani A, Gennaro R. Efficacy and safety evaluation of pentoxifylline associated with other antioxidants in medical treatment of Peyronie's disease: a case-control study. Res Rep Urol. 2015 Dec 31;8:1-10. doi: 10.2147/RRU.S97194. eCollection 2016. PMID: 26770906; PMCID: PMC4706125.
Copy Download .nbib Format: NLM
Subcortical Shape Changes, Hippocampal Atrophy and Cortical Thinning in Future Alzheimer's Disease Patients.

Frontiers in aging neuroscience

Kälin AM, Park MT, Chakravarty MM, Lerch JP, Michels L, Schroeder C, Broicher SD, Kollias S, Nitsch RM, Gietl AF, Unschuld PG, Hock C, Leh SE.
PMID: 28326033
Front Aging Neurosci. 2017 Mar 07;9:38. doi: 10.3389/fnagi.2017.00038. eCollection 2017.

Efficacy of future treatments depends on biomarkers identifying patients with mild cognitive impairment at highest risk for transitioning to Alzheimer's disease. Here, we applied recently developed analysis techniques to investigate cross-sectional differences in subcortical shape and volume alterations in...

Cite
Kälin AM, Park MT, Chakravarty MM, et al. Subcortical Shape Changes, Hippocampal Atrophy and Cortical Thinning in Future Alzheimer's Disease Patients. Front Aging Neurosci. 2017;9:38doi: 10.3389/fnagi.2017.00038.
Kälin, A. M., Park, M. T., Chakravarty, M. M., Lerch, J. P., Michels, L., Schroeder, C., Broicher, S. D., Kollias, S., Nitsch, R. M., Gietl, A. F., Unschuld, P. G., Hock, C., & Leh, S. E. (2017). Subcortical Shape Changes, Hippocampal Atrophy and Cortical Thinning in Future Alzheimer's Disease Patients. Frontiers in aging neuroscience, 938. https://doi.org/10.3389/fnagi.2017.00038
Kälin, Andrea M, et al. "Subcortical Shape Changes, Hippocampal Atrophy and Cortical Thinning in Future Alzheimer's Disease Patients." Frontiers in aging neuroscience vol. 9 (2017): 38. doi: https://doi.org/10.3389/fnagi.2017.00038
Kälin AM, Park MT, Chakravarty MM, Lerch JP, Michels L, Schroeder C, Broicher SD, Kollias S, Nitsch RM, Gietl AF, Unschuld PG, Hock C, Leh SE. Subcortical Shape Changes, Hippocampal Atrophy and Cortical Thinning in Future Alzheimer's Disease Patients. Front Aging Neurosci. 2017 Mar 07;9:38. doi: 10.3389/fnagi.2017.00038. eCollection 2017. PMID: 28326033; PMCID: PMC5339600.
Copy Download .nbib Format: NLM
Spatial Separation of Charge Carriers in In2O3-x(OH)y Nanocrystal Superstructures for Enhanced Gas-Phase Photocatalytic Activity.

ACS nano

He L, Wood TE, Wu B, Dong Y, Hoch LB, Reyes LM, Wang D, Kübel C, Qian C, Jia J, Liao K, O'Brien PG, Sandhel A, Loh JY, Szymanski P, Kherani NP, Sum TC, Mims CA, Ozin GA.
PMID: 27159793
ACS Nano. 2016 May 24;10(5):5578-86. doi: 10.1021/acsnano.6b02346. Epub 2016 May 12.

The development of strategies for increasing the lifetime of photoexcited charge carriers in nanostructured metal oxide semiconductors is important for enhancing their photocatalytic activity. Intensive efforts have been made in tailoring the properties of the nanostructured photocatalysts through different...

Cite
He L, Wood TE, Wu B, et al. Spatial Separation of Charge Carriers in In2O3-x(OH)y Nanocrystal Superstructures for Enhanced Gas-Phase Photocatalytic Activity. ACS Nano. 2016;10(5):5578-86doi: 10.1021/acsnano.6b02346.
He, L., Wood, T. E., Wu, B., Dong, Y., Hoch, L. B., Reyes, L. M., Wang, D., Kübel, C., Qian, C., Jia, J., Liao, K., O'Brien, P. G., Sandhel, A., Loh, J. Y., Szymanski, P., Kherani, N. P., Sum, T. C., Mims, C. A., & Ozin, G. A. (2016). Spatial Separation of Charge Carriers in In2O3-x(OH)y Nanocrystal Superstructures for Enhanced Gas-Phase Photocatalytic Activity. ACS nano, 10(5), 5578-86. https://doi.org/10.1021/acsnano.6b02346
He, Le, et al. "Spatial Separation of Charge Carriers in In2O3-x(OH)y Nanocrystal Superstructures for Enhanced Gas-Phase Photocatalytic Activity." ACS nano vol. 10,5 (2016): 5578-86. doi: https://doi.org/10.1021/acsnano.6b02346
He L, Wood TE, Wu B, Dong Y, Hoch LB, Reyes LM, Wang D, Kübel C, Qian C, Jia J, Liao K, O'Brien PG, Sandhel A, Loh JY, Szymanski P, Kherani NP, Sum TC, Mims CA, Ozin GA. Spatial Separation of Charge Carriers in In2O3-x(OH)y Nanocrystal Superstructures for Enhanced Gas-Phase Photocatalytic Activity. ACS Nano. 2016 May 24;10(5):5578-86. doi: 10.1021/acsnano.6b02346. Epub 2016 May 12. PMID: 27159793.
Copy Download .nbib Format: NLM
Distinct Nucleation and Growth Kinetics of Amorphous SrTiO.

ACS applied materials & interfaces

Chen Y, Yusuf MH, Guan Y, Jacobson RB, Lagally MG, Babcock SE, Kuech TF, Evans PG.
PMID: 29094920
ACS Appl Mater Interfaces. 2017 Nov 22;9(46):41034-41042. doi: 10.1021/acsami.7b12978. Epub 2017 Nov 13.

Integration of emerging complex-oxide compounds into sophisticated nanoscale single-crystal geometries faces significant challenges arising from the kinetics of vapor-phase thin-film epitaxial growth. A comparison of the crystallization of the model perovskite SrTiO

Cite
Chen Y, Yusuf MH, Guan Y, et al. Distinct Nucleation and Growth Kinetics of Amorphous SrTiO. ACS Appl Mater Interfaces. 2017;9(46):41034-41042doi: 10.1021/acsami.7b12978.
Chen, Y., Yusuf, M. H., Guan, Y., Jacobson, R. B., Lagally, M. G., Babcock, S. E., Kuech, T. F., & Evans, P. G. (2017). Distinct Nucleation and Growth Kinetics of Amorphous SrTiO. ACS applied materials & interfaces, 9(46), 41034-41042. https://doi.org/10.1021/acsami.7b12978
Chen, Yajin, et al. "Distinct Nucleation and Growth Kinetics of Amorphous SrTiO." ACS applied materials & interfaces vol. 9,46 (2017): 41034-41042. doi: https://doi.org/10.1021/acsami.7b12978
Chen Y, Yusuf MH, Guan Y, Jacobson RB, Lagally MG, Babcock SE, Kuech TF, Evans PG. Distinct Nucleation and Growth Kinetics of Amorphous SrTiO. ACS Appl Mater Interfaces. 2017 Nov 22;9(46):41034-41042. doi: 10.1021/acsami.7b12978. Epub 2017 Nov 13. PMID: 29094920.
Copy Download .nbib Format: NLM
Molecular Modeling of Structures and Interaction of Human Corticotropin-Releasing Factor (CRF) Binding Protein and CRF Type-2 Receptor.

Frontiers in endocrinology

Slater PG, Gutierrez-Maldonado SE, Gysling K, Lagos CF.
PMID: 29515519
Front Endocrinol (Lausanne). 2018 Feb 20;9:43. doi: 10.3389/fendo.2018.00043. eCollection 2018.

The corticotropin-releasing factor (CRF) system is a key mediator of the stress response and addictive behavior. The CRF system includes four peptides: The CRF system includes four peptides: CRF, urocortins I-III, CRF binding protein (CRF-BP) that binds CRF with...

Cite
Slater PG, Gutierrez-Maldonado SE, Gysling K, et al. Molecular Modeling of Structures and Interaction of Human Corticotropin-Releasing Factor (CRF) Binding Protein and CRF Type-2 Receptor. Front Endocrinol (Lausanne). 2018;9:43doi: 10.3389/fendo.2018.00043.
Slater, P. G., Gutierrez-Maldonado, S. E., Gysling, K., & Lagos, C. F. (2018). Molecular Modeling of Structures and Interaction of Human Corticotropin-Releasing Factor (CRF) Binding Protein and CRF Type-2 Receptor. Frontiers in endocrinology, 943. https://doi.org/10.3389/fendo.2018.00043
Slater, Paula G, et al. "Molecular Modeling of Structures and Interaction of Human Corticotropin-Releasing Factor (CRF) Binding Protein and CRF Type-2 Receptor." Frontiers in endocrinology vol. 9 (2018): 43. doi: https://doi.org/10.3389/fendo.2018.00043
Slater PG, Gutierrez-Maldonado SE, Gysling K, Lagos CF. Molecular Modeling of Structures and Interaction of Human Corticotropin-Releasing Factor (CRF) Binding Protein and CRF Type-2 Receptor. Front Endocrinol (Lausanne). 2018 Feb 20;9:43. doi: 10.3389/fendo.2018.00043. eCollection 2018. PMID: 29515519; PMCID: PMC5826306.
Copy Download .nbib Format: NLM
Bisphenol S impairs blood functions and induces cardiovascular risks in rats.

Toxicology reports

Pal S, Sarkar K, Nath PP, Mondal M, Khatun A, Paul G.
PMID: 29152460
Toxicol Rep. 2017 Oct 20;4:560-565. doi: 10.1016/j.toxrep.2017.10.006. eCollection 2017.

Bisphenol S (BPS) is an industrial chemical which is recently used to replace the potentially toxic Bisphenol A (BPA) in making polycarbonate plastics, epoxy resins and thermal receipt papers. The probable toxic effects of BPS on the functions of...

Cite
Pal S, Sarkar K, Nath PP, et al. Bisphenol S impairs blood functions and induces cardiovascular risks in rats. Toxicol Rep. 2017;4:560-565doi: 10.1016/j.toxrep.2017.10.006.
Pal, S., Sarkar, K., Nath, P. P., Mondal, M., Khatun, A., & Paul, G. (2017). Bisphenol S impairs blood functions and induces cardiovascular risks in rats. Toxicology reports, 4560-565. https://doi.org/10.1016/j.toxrep.2017.10.006
Pal, Sanghamitra, et al. "Bisphenol S impairs blood functions and induces cardiovascular risks in rats." Toxicology reports vol. 4 (2017): 560-565. doi: https://doi.org/10.1016/j.toxrep.2017.10.006
Pal S, Sarkar K, Nath PP, Mondal M, Khatun A, Paul G. Bisphenol S impairs blood functions and induces cardiovascular risks in rats. Toxicol Rep. 2017 Oct 20;4:560-565. doi: 10.1016/j.toxrep.2017.10.006. eCollection 2017. PMID: 29152460; PMCID: PMC5671619.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 2222 entries